Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000622873 | SCV000847819 | uncertain significance | Inborn genetic diseases | 2016-10-07 | criteria provided, single submitter | clinical testing | The p.K1305Q variant (also known as c.3913A>C), located in coding exon 11 of the ATRX gene, results from an A to C substitution at nucleotide position 3913. The lysine at codon 1305 is replaced by glutamine, an amino acid with similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6499 samples with coverage at this position. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |
Labcorp Genetics |
RCV000863037 | SCV001003629 | benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2024-07-06 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001449593 | SCV001652768 | uncertain significance | Intellectual disability-hypotonic facies syndrome, X-linked, 1 | 2021-05-18 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000863037 | SCV001453022 | likely benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2020-06-03 | no assertion criteria provided | clinical testing |